The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses

International Journal of Cancer

Volumn 137, Issue 4, 2015, Pages 819-825

  Kim, Soo Young ^a   Choi, Yoon Young ^a   An, Ji Yeong ^a   Shin, Hyun Beak ^a   Jo, Ara ^b   Choi, Hyeji ^b   Seo, Sang Hyuk ^a   Bang, Hui Jae ^a   Cheong, Jae Ho ^a   Hyung, Woo Jin ^a   Noh, Sung Hoon ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

chemotherapy; gastric cancer; microsatellite instability; prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; STOMACH CANCER; TUMOR VOLUME; AGED; DRUG THERAPY; GENETICS; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PATHOLOGY; PROGNOSIS; STOMACH NEOPLASMS;

ADULT; AGED; DRUG THERAPY; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC METASTASIS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; STOMACH NEOPLASMS;

EID: 84931563601     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29449     Document Type: Article

References (28)

1. Lee HS, Choi SI, Lee HK, et al., Distinct clinical features and outcomes of gastric cancers with microsatellite instability. Mod Pathol 2002; 15: 632-40.
2. Furlan D, Casati B, Cerutti R, et al., Genetic progression in sporadic endometrial and gastrointestinal cancers with high microsatellite instability. J Pathol 2002; 197: 603-9.
3. Merok MA, Ahlquist T, Royrvik EC, et al., Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol 2013; 24: 1274-82.
4. Popat S, Hubner R, Houlston RS,. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-18.
5. Black D, Soslow RA, Levine DA, et al., Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol 2006; 24: 1745-53.
6. An JY, Kim H, Cheong JH, et al., Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer 2012; 131: 505-11.
7. Beghelli S, de Manzoni G, Barbi S, et al., Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery 2006; 139: 347-56.
8. Miyoshi E, Haruma K, Hiyama T, et al., Microsatellite instability is a genetic marker for the development of multiple gastric cancers. Int J Cancer 2001; 95: 350-3.
9. Lee HS, Lee BL, Kim SH, et al., Microsatellite instability in synchronous gastric carcinomas. Int J Cancer 2001; 91: 619-24.
10. Choi YY, Bae JM, An JY, et al., Is microsatellite instability a prognostic marker in gastric cancer?: a systematic review with meta-analysis. J Surg Oncol 2014; 110: 129-35.
11. Nakajima T, Nashimoto A, Kitamura M, et al., Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group. Lancet 1999; 354: 273-7.
12. Cunningham D, Chua YJ,. East meets west in the treatment of gastric cancer. N Engl J Med 2007; 357: 1863-5.
13. Sobin LH, Compton CC,. TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer. Cancer 2010; 116: 5336-9.
14. Leite M, Corso G, Sousa S, et al., MSI phenotype and MMR alterations in familial and sporadic gastric cancer. Int J Cancer 2011; 128: 1606-13.
15. Sobin LH, Wittekind CH, eds. TNM classification of malignant tumors, 6th edn. New York: Wiley-Liss, 2002.
16. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 2011; 14: 113-23.
17. Bol CR, Thibodeau SN, Hamilton SR, et al., A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-57.
18. Dolcetti R, Viel A, Doglioni C, et al., High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999; 154: 1805-13.
19. Phillips SM, Banerjea A, Feakins R, et al., Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic. Br J Surg 2004; 91: 469-75.
20. Prall F, Duhrkop T, Weirich V, et al., Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 2004; 35: 808-16.
21. Watanabe H, Enjoji M, Imai T,. Gastric carcinoma with lymphoid stroma. Its morphologic characteristics and prognostic correlations. Cancer 1976; 38: 232-43.
22. Grogg KL, Lohse CM, Pankratz VS, et al., Lymphocyte-rich gastric cancer: associations with Epstein-Barr virus, microsatellite instability, histology, and survival. Mod Pathol 2003; 16: 641-51.
23. Kim H, An JY, Noh SH, et al., High microsatellite instability predicts good prognosis in intestinal-type gastric cancers. J Gastroenterol Hepatol 2011; 26: 585-92.
24. Group G, Paoletti X, Oba K, et al., Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010; 303: 1729-37.
25. Bang YJ, Kim YW, Yang HK, et al., Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379: 315-21.
26. Cunningham D, Allum WH, Stenning SP, et al., Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
27. Macdonald JS, Smalley SR, Benedetti J, et al., Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30.
28. Sakuramoto S, Sasako M, Yamaguchi T, et al., Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-20.